Kamin Amends Psychemedics Stake Filing
Ticker: PMDI · Form: SC 13D/A · Filed: Dec 5, 2024 · CIK: 806517
| Field | Detail |
|---|---|
| Company | Psychemedics Corp (PMDI) |
| Form Type | SC 13D/A |
| Filed Date | Dec 5, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.005, $3,312,824 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 13D-filing, ownership-change, amendment
TL;DR
Kamin updated his Psychemedics stake filing on Dec 3. Watch for potential moves.
AI Summary
Peter H. Kamin, through an amendment filed on December 3, 2024, has updated his Schedule 13D filing for Psychemedics Corporation. The filing indicates a change in beneficial ownership of the company's common stock. Kamin's address is listed as 2720 Donald Ross Road, #311, Palm Beach Gardens, FL 33410.
Why It Matters
Schedule 13D filings are crucial for investors as they disclose significant ownership changes, potentially signaling shifts in control or strategy for the company.
Risk Assessment
Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in control, which can introduce volatility.
Key Players & Entities
- Peter H. Kamin (person) — Filing party and beneficial owner
- Psychemedics Corporation (company) — Subject company
- David E. Danovitch, Esq. (person) — Authorized to receive notices
- Sullivan & Worcester LLP (company) — Legal counsel
FAQ
What is the specific change in beneficial ownership being reported in this amendment?
The filing is an amendment (Amendment No. 8) to a Schedule 13D, indicating a change in beneficial ownership, but the exact percentage or number of shares acquired or disposed of is not detailed in the provided header information.
When was the event that required this filing to be made?
The date of the event which requires filing of this statement is December 3, 2024.
What is the CUSIP number for Psychemedics Corporation's common stock?
The CUSIP number for Psychemedics Corporation's common stock is 744375205.
Who is authorized to receive notices and communications regarding this filing?
David E. Danovitch, Esq. of Sullivan & Worcester LLP is authorized to receive notices and communications.
What is the primary business of Psychemedics Corporation?
Psychemedics Corporation is in the Services-Medical Laboratories industry, SIC code 8071.
Filing Stats: 1,323 words · 5 min read · ~4 pages · Grade level 8.4 · Accepted 2024-12-05 18:04:48
Key Financial Figures
- $0.005 — ame of Issuer) Common Stock, par value $0.005 per share (Title of Class of Securiti
- $3,312,824 — ted, for an aggregate purchase price of $3,312,824, in connection with the closing of the
Filing Documents
- eps11659_kamin.htm (SC 13D/A) — 48KB
- 0001171520-24-000373.txt ( ) — 49KB
Security and Issuer
Item 1. Security and Issuer. The information contained in “Item 1. Security and Issuer.” of the Schedule 13D is not being amended by this Amendment No. 8.
Identity and Background
Item 2. Identity and Background. The information contained in “Item 2. Identity and Background.” of the Schedule 13D is not being amended by this Amendment No. 8.
Source or Amount of Funds or Other Consideration
Item 3. Source or Amount of Funds or Other Consideration. “Item 3. Source or Amount of Funds or Other Consideration.” of the Schedule 13D is being amended by this Amendment No. 8 to add the following: As described in Item 4, on December 3, 2024, 3K Limited acquired 1,409,712 shares of Common Stock using working capital.
Purpose of Transaction
Item 4. Purpose of Transaction. “Item 4. Purpose of Transaction.” of the Schedule 13D is being amended by this Amendment No. 8 to add the following: Purchase Agreement Closing On December 3, 2024, the Issuer issued 1,409,712 shares of Common Stock to 3K Limited, for an aggregate purchase price of $3,312,824, in connection with the closing of the Stock Sale based on the estimated purchase price, required for the Issuer’s purchase of fractional shares in its reverse stock split effected on December 3, 2024. SCHEDULE 13D/A CUSIP NO. 744375205 Page 2 of 4
Interest in Securities of the Issuer
Item 5. Interest in Securities of the Issuer. “Item 5. Interest in Securities of the Issuer.” of the Schedule 13D is being amended by this Amendment No. 8 as follows: (a) The percentage ownership of shares of Common Stock set forth in this Amendment No. 8 is based upon 5,894,461 shares outstanding as of the close of business on December 3, 2024, which is the total number of shares outstanding as indicated to the Reporting Person by the Issuer. (b) The Reporting Person has the sole voting power and sole dispositive power with respect to all 2,057,449 shares of Common Stock held by him, the Trusts and 3K Limited. (c) Except as set forth in Item 4 of this Amendment No. 8, the Reporting Person has not engaged in any transaction with respect to the Common Stock during the sixty days prior to the date of filing this Amendment No. 8. (d) Not Applicable. (e) Not Applicable.
Contracts, Arrangements, Understandings or Relationships
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. The information contained in “Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.” of the Schedule 13D is not being amended by this Amendment No. 8.
Material to be filed as Exhibits
Item 7. Material to be filed as Exhibits. The information contained in “Item 7. Material to be filed as Exhibits.” of the Schedule 13D is not being amended by this Amendment No. 8. SCHEDULE 13D/A CUSIP NO. 744375205 Page 2 of 4
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: December 5, 2024 /s/ Peter H. Kamin Peter H. Kamin